NEW YORK (GenomeWeb) – Sera Prognostics said this week that it will roll out a limited commercial launch of its PreTRM proteomic test this fall for assessing women's risk of preterm birth.

With the launch, the company becomes the second company to bring a multiplexed, MRM mass spec-based proteomic test to market, following in the footsteps of Integrated Diagnostics, which launched its Xpresys Lung cancer test in 2013.

Sera will use the limited launch to collect a variety of data on the test, Gregory Critchfield, the company's chairman and CEO, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.